Press Releases and Events
EVENTS
Past Events
Event | June 3, 2024 — 4:30 PM ET
Crinetics Pharmaceuticals Announces Positive Initial Findings for Atumelnant in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing's Syndrome
WEBCAST
PRESENTATION
Event | May 9, 2024 — 4:30 PM ET
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Event | March 19, 2024 — 8:30 AM ET
Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study
Event | March 12, 2024 — 4:30 PM ET
Crinetics Presents Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome
Event | February 28, 2024 — 4:30 PM ET
Crinetics Pharmaceuticals To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024
Event | December 18, 2023 — 5:00 PM ET
Crinetics Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Event | September 11, 2023 — 7:30 AM ET
Crinetics Topline Results from Paltusotine Phase 3 PATHFNDR-1 Study
Transforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
